WEBULL

How Thermo Fisher Scientific’s (TMO) Upbeat 2025 Guidance and Strong Q2 Results Have Changed Its Investment Story

Simply Wall St · 08/08/2025 14:19
  • Thermo Fisher Scientific recently raised its full-year 2025 financial guidance after posting second-quarter results that modestly exceeded expectations, with operating margin and EPS forecasts both lifted and free cash flow projected at US$7–7.4 billion.
  • Continued disciplined acquisitions, strong international performance, particularly in Europe where revenues surpassed analyst forecasts, and active industry engagement are helping to strengthen the company's outlook and market position.
  • Let’s examine how Thermo Fisher’s improved guidance following its quarterly results influences the company’s long-term investment narrative and growth prospects.

Find companies with promising cash flow potential yet trading below their fair value.

Thermo Fisher Scientific Investment Narrative Recap

To be a shareholder in Thermo Fisher Scientific, you need to believe in its ability to sustain long-term growth through disciplined acquisitions, compelling innovations, and market leadership in life sciences tools and services. The company’s raised 2025 guidance, following a modest earnings beat, supports an improved short-term outlook, but issues like continued weakness in China and margin pressures remain, these risks could outweigh recent positive momentum if left unresolved.

Among recent announcements, Thermo Fisher’s strategic partnership with Sanofi stands out. This collaboration expands pharmaceutical manufacturing capabilities in the US and supports a key growth catalyst: deeper integration with high-growth biopharma and clinical research, which can enhance recurring revenue streams and offset cyclical weakness elsewhere.

However, despite upbeat results, investors should also weigh the sustained margin pressures from tariffs and foreign exchange...

Read the full narrative on Thermo Fisher Scientific (it's free!)

Thermo Fisher Scientific's narrative projects $49.8 billion revenue and $8.9 billion earnings by 2028. This requires 4.8% yearly revenue growth and a $2.3 billion earnings increase from $6.6 billion today.

Uncover how Thermo Fisher Scientific's forecasts yield a $554.52 fair value, a 22% upside to its current price.

Exploring Other Perspectives

TMO Community Fair Values as at Aug 2025
TMO Community Fair Values as at Aug 2025

Thirteen members of the Simply Wall St Community have set fair value estimates for Thermo Fisher Scientific ranging from US$400 up to US$666.23 per share. While many focus on potential for margin expansion and innovation, you can explore how these views compare or contrast with margin headwinds from global trade and currency shifts.

Explore 13 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth as much as 47% more than the current price!

Build Your Own Thermo Fisher Scientific Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.